ITI Pharma & Healthcare Fund - Growth - Direct Plan has delivered CAGR and average rolling returns as follows :
| 1 Year | 3 Year | 5 Year | 9 Year | |
| CAGR(%) | 3.39 | 20.05 | N/A | N/A |
| Average Rolling Returns(%) | 19.52 | 19.33 | N/A | N/A |
The Current NAV of ITI Pharma & Healthcare Fund - Growth - Direct Plan is ₹18.30.
It is better to invest in a fund with a longer track record as ITI Pharma & Healthcare Fund - Growth - Direct Plan cannot be assessed for consistency of out-performance. Funds returns are more likely to be different than its benchmark NIFTY 500 returns, as Funds portfolio is significantly different.
ITI Pharma & Healthcare Fund - Growth - Direct Plan fund’s expense ratio is 0.66%
The process for redemption is
The AUM of ITI Pharma & Healthcare Fund - Growth - Direct Plan is currently ₹238 Crores.
The Top three stocks are Sun Pharma Inds., Divis Lab and Apollo Hospital Ent. and account for 29% of its portfolio. Top 5 and 10 stocks of fund account for 39% and 59% of fund’s portfolio respectively.
Top three sectors of ITI Pharma & Healthcare Fund - Growth - Direct Plan fund are Healthcare, Chemicals and Miscellaneous accounting for 96% of the total portfolio.
Funds Portfolio Quality is Very Good. It has a large proportion of Green Stocks.Since this is a Equity - Sectoral Fund - Pharma & Health Care it is comparatively safer to invest in this fund. However, since it has not consistently outperformed its benchmark index on an average 3-year rolling returns basis it is not the most suitable fund for SIP.
The category of ITI Pharma & Healthcare Fund - Growth - Direct Plan Fund is Equity - Sectoral Fund - Pharma & Health Care.
Animesh Singh and Nilay Dalal manage the ITI Pharma & Healthcare Fund - Growth - Direct Plan Fund.
ITI Pharma & Healthcare Fund - Growth - Direct Plan current PE ratio is 54.42 and PB ratio is 7.97
The asset allocation of ITI Pharma & Healthcare Fund - Growth - Direct Plan is Stocks : 98%, Debt : 1.99% and Gold : 0%
The minimum SIP amount for ITI Pharma & Healthcare Fund - Growth - Direct Plan is ₹500.00 and minimum lumpsum is ₹5000.00
The exit load for ITI Pharma & Healthcare Fund - Growth - Direct Plan is 0.50% on or before 3 months, NIL after 3 months
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: